Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

Eyebright Medical's Loong Crystal PR IOL received Class III certification from China's NMPA, indicating high regulatory ...

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss deep learning systems and whether they can distinguish between optic disc drusen and true papilledema ...

ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October ...

The Epithelial Thickness Module is expected to be commercially available in February 2025. According to Heidelberg ...

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, ...

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.